Allergen-specific oral immunotherapy for peanut allergy.

BACKGROUND Peanut allergy is one of the most common forms of food allergy encountered in clinical practice.  In most cases, it does not spontaneously resolve; furthermore, it is frequently implicated in acute life-threatening reactions. The current management of peanut allergy centres on meticulous avoidance of peanuts and peanut-containing foods. Allergen-specific oral immunotherapy (OIT) for peanut allergy aims to induce desensitisation and then tolerance to peanut, and has the potential to revolutionise the management of peanut allergy. However, at present there is still considerable uncertainty about the effectiveness and safety of this approach. OBJECTIVES To establish the effectiveness and safety of OIT in people with IgE-mediated peanut allergy who develop symptoms after peanut ingestion. SEARCH METHODS We searched in the following databases: AMED, BIOSIS, CAB, CINAHL, The Cochrane Library, EMBASE, Global Health, Google Scholar, IndMed, ISI Web of Science, LILACS, MEDLINE, PakMediNet and TRIP. We also searched registers of on-going and unpublished trials. The date of the most recent search was January 2012. SELECTION CRITERIA Randomised controlled trials (RCTs), quasi-RCTs or controlled clinical trials involving children or adults with clinical features indicative of IgE-mediated peanut allergy treated with allergen-specific OIT, compared with control group receiving either placebo or no treatment, were eligible for inclusion. DATA COLLECTION AND ANALYSIS Two review authors independently checked and reviewed titles and abstracts of identified studies and assessed risk of bias. The full text of potentially relevant trials was assessed. Data extraction was independently performed by two reviewers with disagreements resolved through discussion. MAIN RESULTS We found one small RCT, judged to be at low risk of bias, that enrolled 28 children aged 1 to 16 years with evidence of sensitisation to peanut and a clinical history of reaction to peanut within 60 minutes of exposure. The study did not include children who had moderate to severe asthma or who had a history of severe peanut anaphylaxis. Randomisation was in a 2:1 ratio resulting in 19 children being randomised to the intervention arm and nine to the placebo arm. Intervention arm children received OIT with peanut flour and control arm participants received placebo comprising of oat flour. The primary outcome was assessed using a double-blind, placebo controlled oral food challenge (OFC) at approximately one year. No data were available on longer term outcomes beyond the OFC conducted at the end of the study.Because of adverse events, three patients withdrew from the intervention arm before the completion of the study. Therefore, only 16 participants received the full course of peanut OIT, whereas all nine patients receiving placebo completed the trial. The per-protocol analysis found a significant increase in the threshold dose of peanut allergen required to trigger a reaction in those in the intervention arm with all 16 participants able to ingest the maximum cumulative dose of 5000 mg of peanut protein (which the authors equate as being equivalent to approximately 20 peanuts) without developing symptoms, whereas in the placebo group they were able to ingest a median cumulative dose of 280 mg (range: 0 to 1900 mg, P < 0.001) before experiencing symptoms.  Per-protocol analyses also demonstrated that peanut OIT resulted in reductions in skin prick test size (P < 0.001), interleukin-5 (P = 0.01), interleukin-13 (P = 0.02) and an increase in peanut-specific immunoglobulin G(4) (IgG(4)) (P < 0.01).Children in the intervention arm experienced more adverse events during treatment than those in the placebo arm. In the initial day escalation phase, nine (47%) of the 19 participants initially enrolled in the OIT arm experienced clinically-relevant adverse events which required treatment with H(1)-antihistamines, two of which required additional treatment with epinephrine (adrenaline). AUTHORS' CONCLUSIONS The one small RCT we found showed that allergen-specific peanut OIT can result in desensitisation in children, and that this is associated with evidence of underlying immune-modulation. However, this treatment approach was associated with a substantial risk of adverse events, although the majority of these were mild.  In view of the risk of adverse events and the lack of evidence of long-term benefits, allergen-specific peanut OIT cannot currently be recommended as a treatment for the management of patients with IgE-mediated peanut allergy.  Larger RCTs are needed to investigate the acceptability, long-term effectiveness and cost-effectiveness of safer treatment regimens, particularly in relation to the induction of clinical and immunological tolerance.

[1]  A. Sheikh,et al.  Oral immunotherapy for the treatment of peanut allergy: systematic review of six case series studies. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

[2]  A. Sheikh,et al.  Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta‐analysis , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[3]  J. Deighton,et al.  Efficacy and safety of high‐dose peanut oral immunotherapy with factors predicting outcome , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[4]  A. Sheikh,et al.  Epinephrine auto‐injector use in adolescents at risk of anaphylaxis: a qualitative study in Scotland, UK , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[5]  A. Sheikh,et al.  Immunotherapy: The meta-analyses. What have we Learned? , 2011, Immunology and allergy clinics of North America.

[6]  D. Moneret-Vautrin Immunothérapie sublinguale et orale de l'allergie alimentaire: effets cliniques et signification des modifications immunologiques , 2011 .

[7]  A. Sheikh,et al.  World Allergy Organization anaphylaxis guidelines: summary. , 2011, The Journal of allergy and clinical immunology.

[8]  A. Burks,et al.  Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. , 2011, The Journal of allergy and clinical immunology.

[9]  Aziz Sheikh,et al.  Incidence, prevalence, and trends of general practitioner-recorded diagnosis of peanut allergy in England, 2001 to 2005. , 2011, The Journal of allergy and clinical immunology.

[10]  A. Kemper,et al.  A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. , 2011, The Journal of allergy and clinical immunology.

[11]  Anne-Louise Ponsonby,et al.  Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. , 2011, The Journal of allergy and clinical immunology.

[12]  K. Nadeau,et al.  The Safety of Peanut Oral Immunotherapy in Peanut Allergic Subjects in a Single Center Trial , 2011 .

[13]  A. Burks,et al.  Evidence of Desensitization by Sublingual Immunotherapy in Peanut-Allergic Children , 2011 .

[14]  S. Durham,et al.  Sublingual immunotherapy for allergic rhinitis , 2010 .

[15]  N. Petit,et al.  Efficacité et sécurité des protocoles de tolérance à l’arachide (immunothérapie orale). Étude pilote sur 51 patients , 2010 .

[16]  B. Niggemann,et al.  Oral peanut immunotherapy in children with peanut anaphylaxis. , 2010, The Journal of allergy and clinical immunology.

[17]  A. Burks,et al.  Peanut oral immunotherapy is not ready for clinical use. , 2010, The Journal of allergy and clinical immunology.

[18]  G. Toit,et al.  Specific oral tolerance induction in food allergic children: is oral desensitisation more effective than allergen avoidance? , 2010, Archives of Disease in Childhood.

[19]  U. Nurmatov,et al.  Oral immunotherapy for peanut allergy , 2010, BMJ : British Medical Journal.

[20]  J. Godbold,et al.  US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. , 2010, The Journal of allergy and clinical immunology.

[21]  G. Roberts,et al.  Management of nut allergy influences quality of life and anxiety in children and their mothers , 2010, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[22]  P. Smith,et al.  Immunoglobulin Changes using Different Dosing Regimens of Peanut Oral Immunotherapy (OIT) in Peanut Allergic Subjects , 2010 .

[23]  A. Kemper,et al.  Double-Blinded Placebo Controlled Sublingual Immunotherapy (SLIT) Trial for Peanut Allergy , 2010 .

[24]  R. Wasserman,et al.  Office Based Oral Desensitization of Patients With Non-Anaphylactic Sensitivity to Foods Is Safe and Effective , 2010 .

[25]  F. Simons,et al.  Anaphylaxis: Recent advances in assessment and treatment. , 2009, The Journal of allergy and clinical immunology.

[26]  M. Fenton,et al.  Summary of the 2008 National Institute of Allergy and Infectious Diseases-US Food and Drug Administration Workshop on Food Allergy Clinical Trial Design. , 2009, The Journal of allergy and clinical immunology.

[27]  S. Durham,et al.  Clinical efficacy and immune regulation with peanut oral immunotherapy. , 2009, The Journal of allergy and clinical immunology.

[28]  A. Burks,et al.  Safety of a peanut oral immunotherapy protocol in children with peanut allergy. , 2009, The Journal of allergy and clinical immunology.

[29]  J. Deighton,et al.  Successful oral tolerance induction in severe peanut allergy , 2009, Allergy.

[30]  L. Joseph,et al.  Is the prevalence of peanut allergy increasing? A 5-year follow-up study in children in Montreal. , 2009, The Journal of allergy and clinical immunology.

[31]  J. Hourihane,et al.  Impact of peanut allergy on quality of life, stress and anxiety in the family , 2009, Allergy.

[32]  R. Mullins,et al.  Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007. , 2009, The Journal of allergy and clinical immunology.

[33]  A. Clark,et al.  Good prognosis, clinical features, and circumstances of peanut and tree nut reactions in children treated by a specialist allergy center. , 2008, The Journal of allergy and clinical immunology.

[34]  J. Soar,et al.  Emergency treatment of anaphylactic reactions--guidelines for healthcare providers. , 2008, Resuscitation.

[35]  A. Burks,et al.  Oral Peanut Immunotherapy for Children with Peanut Allergy , 2008 .

[36]  H. Sampson,et al.  Peanut allergy: emerging concepts and approaches for an apparent epidemic. , 2007, The Journal of allergy and clinical immunology.

[37]  A. Sheikh,et al.  The psychosocial impact of anaphylaxis on young people and their parents , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[38]  K. Grimshaw,et al.  The impact of government advice to pregnant mothers regarding peanut avoidance on the prevalence of peanut allergy in United Kingdom children at school entry. , 2007, The Journal of allergy and clinical immunology.

[39]  J. Rolland,et al.  The peanut allergy epidemic: allergen molecular characterisation and prospects for specific therapy , 2007, Expert Reviews in Molecular Medicine.

[40]  L. Joseph,et al.  Accidental ingestions in children with peanut allergy. , 2006, The Journal of allergy and clinical immunology.

[41]  L. Mansfield Successful oral desensitization for systemic peanut allergy. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[42]  S. Sicherer,et al.  Risk-taking and Coping Strategies of Food Allergic Adolescents and Young Adults , 2006 .

[43]  A. Burks,et al.  Oral Desensitization and Induction of Tolerance in Peanut-Allergic Children , 2006 .

[44]  Hugh A Sampson,et al.  9. Food allergy. , 2003, The Journal of allergy and clinical immunology.

[45]  George Davey Smith,et al.  Meta-analysis: Principles and procedures , 1997, BMJ.

[46]  H. Nelson,et al.  Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. , 1997, The Journal of allergy and clinical immunology.

[47]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[48]  H. Nelson,et al.  Treatment of peanut allergy with rush immunotherapy. , 1992, The Journal of allergy and clinical immunology.

[49]  A. Schofield A case of egg poisoning , 1908 .

[50]  A. Sheikh,et al.  Oral immunotherapy for peanut allergy , 2011 .

[51]  A. Woodcock,et al.  Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. , 2010, The Journal of allergy and clinical immunology.